These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21939364)

  • 21. A target-dose finding study of clozapine in patients with schizophrenia.
    Bennett JA; Keck PE
    Ann Clin Psychiatry; 1996 Mar; 8(1):19-21. PubMed ID: 8743644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.
    Yusufi B; Mukherjee S; Flanagan R; Paton C; Dunn G; Page E; Barnes TR
    Int Clin Psychopharmacol; 2007 Jul; 22(4):238-43. PubMed ID: 17519648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clozapine plasma level monitoring: current status.
    Cooper TB
    Psychiatr Q; 1996; 67(4):297-311. PubMed ID: 8938830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing treatment with clozapine.
    Conley RR
    J Clin Psychiatry; 1998; 59 Suppl 3():44-8. PubMed ID: 9541338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram.
    Perry PJ; Bever KA; Arndt S; Combs MD
    Biol Psychiatry; 1998 Oct; 44(8):733-8. PubMed ID: 9798077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [No given alternatives to clozapine in treatment-resistant schizophrenia].
    Eriksen J; Rosenborg S
    Lakartidningen; 2013 Oct 9-15; 110(41):1809. PubMed ID: 24187896
    [No Abstract]   [Full Text] [Related]  

  • 27. Absolute and Dose-Adjusted Serum Concentrations of Clozapine in Patients Switching vs. Maintaining Treatment: An Observational Study of 1979 Patients.
    Kyllesø L; Smith RL; Karlstad Ø; Andreassen OA; Molden E
    CNS Drugs; 2021 Sep; 35(9):999-1008. PubMed ID: 34417726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using therapeutic drug monitoring to personalize clozapine dosing in Asians.
    de Leon J; Schoretsanitis G; Kane JM; Ruan CJ
    Asia Pac Psychiatry; 2020 Jun; 12(2):e12384. PubMed ID: 32119764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of treatment resistant schizophrenia unresponsive to clozapine.
    Barnes TR; McEvedy CJ; Nelson HE
    Br J Psychiatry Suppl; 1996 Dec; (31):31-40. PubMed ID: 8968653
    [No Abstract]   [Full Text] [Related]  

  • 30. The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy.
    Costa-Dookhan KA; Agarwal SM; Chintoh A; Tran VN; Stogios N; Ebdrup BH; Sockalingam S; Rajji TK; Remington GJ; Siskind D; Hahn MK
    Expert Opin Drug Saf; 2020 Jan; 19(1):43-57. PubMed ID: 31770500
    [No Abstract]   [Full Text] [Related]  

  • 31. The significance of sampling time in therapeutic drug monitoring of clozapine.
    Jakobsen MI; Larsen JR; Svensson CK; Johansen SS; Linnet K; Nielsen J; Fink-Jensen A
    Acta Psychiatr Scand; 2017 Feb; 135(2):159-169. PubMed ID: 27922183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Importance of determining clozapine plasma level in follow-up of schizophrenic patients].
    Vailleau JL; Jeanny B; Chomard P; Vincent R
    Encephale; 1996; 22(2):103-9. PubMed ID: 8706619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A rapid gas chromatographic method quantitating clozapine in human plasma or serum for the purpose of therapeutic monitoring.
    Jennison TA; Brown P; Crossett J; Kushnir M; Urry FM
    J Anal Toxicol; 1995; 19(7):537-41. PubMed ID: 8577174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NMS after clozapine initiation.
    Skarpathiotakis M; Westreich N
    J Am Acad Child Adolesc Psychiatry; 2005 Nov; 44(11):1101-2. PubMed ID: 16239854
    [No Abstract]   [Full Text] [Related]  

  • 35. Effects of clozapine for non-treatment-resistant patients with schizophrenia.
    Galletly CA; Clark CR; McFarlane AC; Weber DL
    Psychiatr Serv; 1999 Jan; 50(1):101-3. PubMed ID: 9890589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focus on clozapine.
    Naheed M; Green B
    Curr Med Res Opin; 2001; 17(3):223-9. PubMed ID: 11900316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine-induced intestinal occlusion: a serious side effect.
    Pelizza L; De Luca P; La Pesa M; Borella D
    Acta Biomed; 2007 Aug; 78(2):144-8. PubMed ID: 17933283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine in patients with chronic schizophrenia: serum level, EEG and memory performance.
    Adler G; Grieshaber S; Faude V; Thebaldi B; Dressing H
    Pharmacopsychiatry; 2002 Sep; 35(5):190-4. PubMed ID: 12237790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine.
    Buur-Rasmussen B; Brøsen K
    Eur Neuropsychopharmacol; 1999 Dec; 9(6):453-9. PubMed ID: 10625111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Seizure on low-dose clozapine.
    Ravasia S; Dickson RA
    Can J Psychiatry; 1998 May; 43(4):420. PubMed ID: 9598281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.